Literature DB >> 27488109

DNA damage after chronic oxytocin administration in rats: a safety yellow light?

Daniela D Leffa1, Francine Daumann2, Adriani P Damiani2, Arlindo C Afonso3, Maria A Santos3, Thayara H Pedro3, Renan P Souza3, Vanessa M Andrade2.   

Abstract

Adjuvant therapy is a common therapeutic strategy used for schizophrenia management. Oxytocin has shown promising results as antipsychotic adjuvant in patients with schizophrenia. Although short-term clinical studies have indicated tolerability and no major side-effect manifestation, long-term studies remain needed. In this study, we investigated whether oxytocin chronic administration in rats may lead to brain DNA damage by comet assay. Our results suggest that 21 and 56-day treatment with once daily intraperitoneal oxytocin (0.1, 1.0 and 10.0 mg/kg) may cause substantial DNA damage in hippocampus. We have not found differences on body weight gain. Our findings also point that further clinical and preclinical studies evaluating oxytocin safety after chronic exposure are necessary.

Entities:  

Keywords:  Autism; Comet assay; DNA damage; Oxytocin; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27488109     DOI: 10.1007/s11011-016-9885-z

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  31 in total

Review 1.  Oxidative DNA damage: mechanisms, mutation, and disease.

Authors:  Marcus S Cooke; Mark D Evans; Miral Dizdaroglu; Joseph Lunec
Journal:  FASEB J       Date:  2003-07       Impact factor: 5.191

Review 2.  Antipsychotic medication and oxidative cell stress: a systematic review.

Authors:  Peter Lepping; John Delieu; Richard Mellor; John H H Williams; Peter R Hudson; Claire Hunter-Lavin
Journal:  J Clin Psychiatry       Date:  2010-06-29       Impact factor: 4.384

Review 3.  Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.

Authors:  S Miyamoto; N Miyake; L F Jarskog; W W Fleischhacker; J A Lieberman
Journal:  Mol Psychiatry       Date:  2012-05-15       Impact factor: 15.992

4.  Elevated cardiac oxidative stress in newborn rats from mothers treated with atosiban.

Authors:  Yavuz Simsek; Onder Celik; Abdullah Karaer; Ercan Yılmaz; Mehmet Gul; Elif Ozerol; Sedat Bilgic; Nilufer Celik
Journal:  Arch Gynecol Obstet       Date:  2011-08-25       Impact factor: 2.344

Review 5.  Evidence-based pharmacotherapy of schizophrenia.

Authors:  Stefan Leucht; Stephan Heres; Werner Kissling; John M Davis
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-06       Impact factor: 5.176

6.  Hormones in the treatment of psychoses.

Authors:  W Bujanow
Journal:  Br Med J       Date:  1972-11-04

7.  Identification of a primary target of thalidomide teratogenicity.

Authors:  Takumi Ito; Hideki Ando; Takayuki Suzuki; Toshihiko Ogura; Kentaro Hotta; Yoshimasa Imamura; Yuki Yamaguchi; Hiroshi Handa
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

Review 8.  Oxytocin in General Anxiety and Social Fear: A Translational Approach.

Authors:  Inga D Neumann; David A Slattery
Journal:  Biol Psychiatry       Date:  2015-06-10       Impact factor: 13.382

9.  Oxytocin attenuates NADPH-dependent superoxide activity and IL-6 secretion in macrophages and vascular cells.

Authors:  Angela Szeto; Daniel A Nation; Armando J Mendez; Juan Dominguez-Bendala; Larry G Brooks; Neil Schneiderman; Philip M McCabe
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-21       Impact factor: 4.310

Review 10.  The comet assay for DNA damage and repair: principles, applications, and limitations.

Authors:  Andrew R Collins
Journal:  Mol Biotechnol       Date:  2004-03       Impact factor: 2.860

View more
  1 in total

1.  Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review.

Authors:  Marilyn Horta; Kathryn Kaylor; David Feifel; Natalie C Ebner
Journal:  Neurosci Biobehav Rev       Date:  2019-10-21       Impact factor: 8.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.